TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03161197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
Study: NCT03456544

Intervention type: DRUG
Intervention: Vancomycin
Description: Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
Study: NCT01710696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-beta estradiol
Description: 5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-beta estradiol
Description: 0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
Study: NCT01676064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ringer lactate solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: restrictive fluid regime
Study: NCT02845336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib 100mg PO twice per day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artificial tears
Description: Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artificial tears
Description: Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.
Study: NCT00348517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Free Lubricant Eye Drops
Description: 1-2 drops per eye four times per day for 42 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Liquigel Lubricant Eye Drops
Description: 1-2 drops per eye four times per day for 42 days
Study: NCT02324452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (capecitabine or 5-fluorouracil)
Description: Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (capecitabine or 5-fluorouracil)
Description: Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
Study: NCT01839539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic and cytokine-induced killer cells
Study: NCT04418167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSI-1187
Description: JSI-1187 capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSI-1187
Description: JSI-1187 capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSI-1187
Description: JSI-1187 capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib capsules for oral administration
Study: NCT03651336

Intervention type: DEVICE
Group type: OTHER
Intervention: ARGOS-IO Sensor Pressure System
Description: The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
Study: NCT02226250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 Placebo Beverages
Description: Sugar beverage 2 hr before meal, with meal and 2 hr after meal
Study: NCT04567329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV03
Description: 100% perfluorohexyloctane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: 0.6% sodium chloride solution
Study: NCT01316146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.CD30 T cells
Description: Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2~Group Two, 1x10\^8 cells/m\^2~Group Three, 2x10\^8 cells/m\^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc.
Study: NCT03133143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognifit
Description: CogniFit is an Internet browser-based digital brain training program, to improve cognitive abilities based on a personalised brain training regimen. Participants are instructed to play all games assigned by cognifit from three categories (memory, spatial perception, and mental planning) during each training session. After playing the games in these three categories, they are free to choose which exercises they wish to play.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SIMS 4 (Maxis, Inc)
Description: The Sims 4 is a life simulation PC game. It is purely an entertainment game without known cognitive or health-related outcomes. Does not iclude high-intensity action and competition. This specific game and non-competitive games like it in general do not improve attention, working memory, or other cognitive abilities despite being engaging and fun.
Study: NCT01167270

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Child Safety Insights
Description: A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Insights
Description: Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
Study: NCT01756885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial.
Study: NCT00627796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide-Autogel 120 mg
Description: ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were \> 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were \< 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels \<1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
Study: NCT03068780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10
Description: 10% birch bark extract in 90% sunflower oil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control gel
Description: Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
Study: NCT03472196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoZip System
Description: The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight.
Study: NCT00858780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg etanercept once weekly + methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 25mg etanercept once weekly + methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator once weekly + methotrexate
Study: NCT01426360

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control dentifrice
Description: use the dentifrice to brush teeth twice a day for one minute for 3 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strontium chloride/potassium nitrate dentifrice
Description: use the dentifrice to brush teeth twice daily for 3 days
Study: NCT01988636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01011855

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEHC IWS 4400 & Giraffe Warmer beds
Description: Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEHC IWS 4400 & Giraffe Warmer beds
Description: Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEHC IWS 4400 & Giraffe Warmer beds
Description: Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEHC IWS 4400 & Giraffe Warmer beds
Description: Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEHC IWS 4400 & Giraffe warmer beds
Description: Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEHC IWS 4400 & Giraffe Warmer beds
Description: Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
Study: NCT03946787

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) Therapy
Description: The reprocessing and desensitization of each traumatic memory occurs in eight phases. In the first two phases, the therapist identifies targets and develops a treatment plan, enhances and develops personal resources, before working on traumatic memories. In stages 3 to 6, reprocessing and desensitization of memory is done. The patient focuses on the image of the event, negative beliefs and associated bodily sensations, while moving the eyes from side to side, following the therapist's fingers or other dual attention stimuli (eg, manual touch, auditory stimulation). Phases 7 and 8 are closing and reassessing, where the therapist determines if the memory has been processed properly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
Study: NCT01261832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiplatelet therapy
Description: Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiplatelet therapy
Description: Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
Study: NCT00474058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patches
Study: NCT02638922

Intervention type: DRUG
Intervention: Estradiol
Description: Estradiol containing compounds administered orally in a non-randomized manner.
Study: NCT01261832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiplatelet therapy
Description: Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
Study: NCT00214500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl
Study: NCT03085277

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preterm Formula
Description: Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
Study: NCT00586326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MammoSite Radiation Therapy System
Description: The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
Study: NCT04584697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-AMG
Description: COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study: NCT03504579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rt-fMRI neurofeedback
Description: use of real time fMRI neurofeedback to achieve targeted brain changes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: rt-fMRI neurofeedback
Description: use of real time fMRI neurofeedback to achieve targeted brain changes
Study: NCT01451268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
Study: NCT03221075

Intervention type: OTHER
Intervention: Registry
Description: There is no intervention.
Study: NCT02182648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Description: 1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of etomidate at 2 minutes before anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of propofol at 2 minutes before anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: 1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. inhale sevoflurane for anesthesia induction and maintenance
Study: NCT03582644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
Study: NCT00112697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01997710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: all-ceramic inlay-retained RBFDP
Description: Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: all-ceramic RBFDP
Description: Rehabilitation of tooth loss with an all-ceramic RBFDP
Study: NCT01151098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear